---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-24-000090"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:51:59.133261+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# MacroGenics posts corporate presentation with Phase 2 interim data (TAMARACK trial)

## Summary
- Corporate presentation posted May 9, 2024; data cut-off April 12, 2024.
- Presentation includes Phase 2 interim data from TAMARACK trial.
- No specific numerical results disclosed in the 8-K excerpt; full presentation on company website.
- Investors should review the complete presentation for material clinical updates.

## SEC filing metadata
- accession: 0001125345-24-000090
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000090/0001125345-24-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000090/mgnx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-24-000090
- JSON: https://secwatch.observer/filing/0001125345-24-000090.json
- Plain text: https://secwatch.observer/filing/0001125345-24-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.